Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Purchased by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. boosted its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 22.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,119,027 shares of the company's stock after buying an additional 924,027 shares during the quarter. Adage Capital Partners GP L.L.C. owned 3.88% of Centessa Pharmaceuticals worth $85,744,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after acquiring an additional 685,371 shares in the last quarter. Diadema Partners LP acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at $2,209,000. Affinity Asset Advisors LLC raised its stake in Centessa Pharmaceuticals by 13.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock valued at $18,357,000 after purchasing an additional 130,312 shares during the last quarter. XTX Topco Ltd raised its stake in shares of Centessa Pharmaceuticals by 122.9% in the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after buying an additional 12,506 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Institutional investors own 82.01% of the company's stock.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the transaction, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. This represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $13.61, for a total value of $159,808.62. Following the transaction, the insider now owns 122,279 shares of the company's stock, valued at approximately $1,664,217.19. This trade represents a 8.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 213,824 shares of company stock worth $3,497,018 in the last quarter. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Trading Up 0.1 %

Shares of CNTA traded up $0.02 during trading hours on Tuesday, reaching $13.77. The stock had a trading volume of 218,156 shares, compared to its average volume of 606,366. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The firm has a 50-day moving average of $14.38 and a 200 day moving average of $15.86. The company has a market cap of $1.83 billion, a P/E ratio of -8.97 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. On average, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on CNTA shares. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective on the stock. Morgan Stanley reissued an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating on the stock. Finally, Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.